The components of the apoptotic program are targets for anticancer therapy. Bcl-2 protein
inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, …

The immune system, and in particular T cells, can be harnessed to treat cancer. Several
bispecific T cell engaging antibodies of the BiTE ® format are in early or late-stage clinical …

A unique mRNA produced in leukemic cells from at (15; 17) acute promyelocytic leukemia (APL)
patient encodes a fusion protein between the retinoic acid receptor a (RARa) and a …

Background and Methods. Patients with acute promyelocytic leukemia have a characteristic
(15;17) translocation, with a breakpoint on chromosome 17 in the region of the retinoic acid …

The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide
hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (…

… Frankel, Merck Research Laboratories; Cong Chen, Merck Research Laboratories; Justin
L. Ricker, Merck Research Laboratories; Jean Marie Arduino, Merck Research Laboratories …

PURPOSE: To determine the safety and efficacy of arsenic trioxide (ATO) in patients with
relapsed acute promyelocytic leukemia (APL). PATIENTS AND METHODS: Forty patients …

▪Objective: To describe a novel complication of therapy with all-trans retinoic acid in patients
with acute promyelocytic leukemia. ▪Design: Case series. ▪Setting: Comprehensive cancer …

The goal of this phase II multicenter clinical trial was to evaluate a new intensive chemotherapy
program for adults with untreated acute lymphoblastic leukemia (ALL) and to examine …

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active
clinically in cutaneous T-cell lymphoma and preclinically in leukemia. A phase 1 study was …